Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yep 3435 did not make it on the other board.
So much for truth from a so called Christian.
Looks like my new post didn't make it past Morovan
Posted by: INET6
In reply to: lmorovan who wrote msg# 3234
Date:7/27/2005 12:21:18 PM
Post #of 3235
Morovan:
Common sense will tell you and us that the so called 17 million has gone to keep this company alive, It paid salaries it went into purchasing parts it went into purchasing numerous other potential needs that allow a start up company with originally 6 or 7(I believe) members to survive while growing. You can;t sit at a computer in NJ and dictate how monies are being spent,and from what I've seen so far you have no idea of the requirements to spend such sums,
You have no idea of the expenses involved to market even an original toothbrush, let alone a somewhat complicated piece of original equipment. I believe them when they say they were originally working with off the shelf pieces to put things together,because from my past experience in tooling and die work,plus being involved with my own product years back, thst figure over three years is IMO not exorbitant.
Mow they have grown to include high end sales people to try and move this idea forward.
IMO he has been playing it close to the belt,in fact he has to, until he decides to hit the market with more shares,that he IMO is not sure, will be worthy ,in the future.
IMO you have to get away from your seemingly slumlike living(don't know how else to put it) and enter the real world of prosperous people trying to improve their lives even more, while also carrying the ball for others who have had faith in them.
Doesn't it make you wonder why you are so much smarter than every one else,except for a few that admittedly don't or never will own this stock plus a few that justly gave up on it in the early years and are now trying to justify their decision.
,
Public Reply / Private Reply / Keep Previous / Next
Add Board Mark CEXI Add Person Mark INET6 Report TOS Violation
JUST In case ,but I can see that it will not work
Posted by: INET6
In reply to: lmorovan who wrote msg# 3228
Date:7/27/2005 10:46:20 AM
Post #of 3229
Morovan:
A whole post and you stated nothing, but junk coming out of your head.
If Danny lost $110,000,that's his problem for selling for pennies.
I can say I've lost half a million ,but that would not convince anyone.
MP's methods may not meet with your approval, but they do not
drastically upset 98% of the rest of the posters. Holding back information for a tactical reason, may be just common sense,(you doknow what that is don't you?
If that makes you the genious,so be it.
Toss this one and it will show your real colors.
INET6
Public Reply / Private Reply / Keep Previous / Next
Raging Bull is a tool for the shorters, like all message boards. I am glad RB wont come up! How come their is a TOS violation for hyping, and none for out right lying bashing?
They call it hyping when one posts public news and PR's. It doesn't make sense? How come we have a main CDEX message board almost completly full of non CDEX shareholders? Who are always bad mouthing CDEX, and it's real shareholders.
How come a certain party is allowed to post his own website? Is that not hyping his agenda? The truth according to Garp!
I still believe that CDEX/CEXI will blow these naysayers away. Until CDEX comes out with significant news of contracts, parterships, revenues etc. I am not really interested in the message board wars, or what the bashers have to say. Just as I am not interested in what brain warped Liberals have to say. You can't reason with them! Their views on what happened and will happen are either wrong, warped, are corrupted by their own brains or agenda.
They have been having trouble again Inet, it is not you.
Actually I wrote Matt and told him I thought it was a good move on his part to name lmorovan the moderator of the "other board". Since lmorovan was the most vocal of the paranoids over there saying the board had been "compromised", he now knows as will the others that there was never any hidden cabal or group stifling his free speech. Their posts were getting deleted because they violated some TOS of ihub and Matt deleted them, it was that simple.
Now the boards make up is comprised of THE PERMANENTLY BANNED band, about 6 or 7, of non stockholders of CDEX. They are the detritus as a result of the high colonic Raging Bull gave itself a couple of months ago. As with other boards lmorovan has started or had control over, it will die.
The law firm who is handling our patent applications is also the former employer of our newly nominated supreme court justice, John Roberts.
http://en.wikipedia.org/wiki/John_G._Roberts_Jr.
John Glover Roberts, Jr. (born January 27, 1955) is an American attorney, and jurist. He is a judge on the United States Court of Appeals for the District of Columbia Circuit, and, if confirmed by the United States Senate, will become an Associate Justice of the U.S. Supreme Court.
On July 19, 2005, Roberts was nominated by President George W. Bush to replace Sandra Day O'Connor, who advised Bush on July 1 that she would retire from her position as an Associate Justice upon the confirmation of her successor.
Roberts lives in Bethesda, Maryland, and is the first Supreme Court nominee since Stephen Breyer in 1994. He is a practicing Catholic. He has three sisters—Kathy, Peggy and Barbara—and is the second oldest of his siblings. He and his wife, Jane Sullivan Roberts, have two adopted children, Jack and Josie (the latter is a year older than the former). Jane is a past vice-president of Feminists for Life, a pro-life feminist group.
Contents [hide]
1 Life and career
2 Notable Arguments on Behalf of Clients
2.1 As Deputy Solicitor General
2.2 Private Law Practice
3 Judicial Opinions
3.1 During a Confirmation Hearing
3.2 Opinions as Judge on the U.S. Court of Appeals
4 Sources
[edit]
Life and career
Roberts was born in Buffalo, New York, to Jack and Rosemary Roberts. His father was an executive at Bethlehem Steel. Roberts's family moved to Long Beach, Indiana, an affluent town on the coast of Lake Michigan, when Roberts was in second grade.
He graduated first in the class of 1973 from La Lumiere, a small Catholic boarding school near LaPorte, Indiana. He studied six years of Latin and some French and was known for his devotion to his studies. He was co-captain of the football team and described himself as a "slow-footed halfback". He also wrestled, was co-editor of the school paper, served on the athletic council and served on the Executive Committee of the Student Council. Other activities included choral and drama.
He graduated summa ### laude from Harvard College (in three years), with a Bachelor of Arts degree in 1976 and received his law degree magna ### laude from Harvard Law School (where he was managing editor of the Harvard Law Review) in 1979.
After graduation, Roberts became a law clerk for Henry Friendly on the Second Circuit Court of Appeals, and held this post until the following year. From 1980 to 1981, he was a law clerk to then-Associate Justice William Rehnquist on the Supreme Court.
From 1981 to 1982, Roberts was a Special Assistant to U.S. Attorney General William French Smith, under President Ronald Reagan—at the U.S. Department of Justice. In 1982, Roberts became the Associate Counsel to the President under President Reagan's Counsel, Fred Fielding, and held this post until 1986.
Roberts entered private practice in 1986 as an associate at the Washington, D.C.-based Hogan & Hartson law firm, but left to serve under President George H. W. Bush in the Department of Justice from 1989 to 1993 as Deputy Solicitor General. In this capacity, he argued 39 cases before the Supreme Court, winning 25.
1976 Harvard University yearbook photo of Roberts.In 1992, Bush nominated Roberts to the U.S. Court of Appeals for the District of Columbia Circuit, but he was not confirmed; no Senate vote was held. Roberts returned to Hogan & Hartson as a partner in 1993 after Bush was defeated by Bill Clinton in the 1992 presidential election, and became the head of the firm's appellate practice.
Hogan & Hartson advised the George W. Bush campaign during the Florida election recount (see Bush v. Gore).
Roberts was nominated to the Circuit Court of Appeals for the District of Columbia by President George W. Bush on May 9, 2001, but his nomination – along with 29 others – failed to make it out of the Senate Judiciary Committee following prolonged partisan wrangling. He was renominated on January 7, 2003, to replace James L. Buckley. He was confirmed by the U.S. Senate by voice vote on May 8 and received his commission on June 2, 2003. Some Democrats, however, had objected to Roberts's nomination; during the nomination hearing, Senator Edward Kennedy of Massachusetts expressed concern and Senator Charles Schumer of New York criticized Roberts for declining to cite court rulings with which he disagreed.
On July 19, 2005, President Bush nominated Roberts to replace Sandra Day O'Connor as an Associate Justice on the U.S. Supreme Court. Roberts was officially named by Bush in a live, nationwide television broadcast at 9 p.m. EDT in the East Room of the White House, though the choice had already been reported by the Associated Press at 7:44 p.m. EDT, 76 minutes before the official announcement.
Roberts is currently a member of the Federalist Society, the American Law Institute, the American Academy of Appellate Lawyers, the Edward Coke Appellate American Inn of Court, and the National Legal Center for the Public Interest. He serves on the Federal Appellate Rules Advisory Committee.
Roberts would become, if confirmed, the second sitting justice to have graduated from Harvard College (along with David Souter) and the sixth sitting judge to attend Harvard Law School (Souter, Stephen Breyer, Antonin Scalia, and Anthony Kennedy all graduated from Harvard Law School, while Ruth Bader Ginsberg attended there for two years). He would be the 109th justice to serve on the court.
[edit]
Notable Arguments on Behalf of Clients
[edit]
As Deputy Solicitor General
(arguing the positions formulated by the President, the Attorney General and other policy makers)
Abortion. In a brief before the Supreme Court in Rust v. Sullivan (500 U.S. 173, 1991), where he was defending the validity of a government regulation that banned abortion-related counseling by federally-funded family planning programs, Roberts wrote:
"We continue to believe that [Roe v. Wade] was wrongly decided and should be overruled. As more fully explained in our briefs, filed as amicus curiae, in Hodgson v. Minnesota, 110 S. Ct. 2926 (1990); Webster v. Reproductive Health Services, 109 S. Ct. 3040 (1989); Thornburgh v. American College of Obstetricians and Gynecologists, 476 U.S. 747 (1986); and City of Akron v. Akron Center for Reproductive Health, 462 U.S. 416 (1983), the Court's conclusions in Roe that there is a fundamental right to an abortion and that government has no compelling interest in protecting prenatal human life throughout pregnancy find no support in the text, structure, or history of the Constitution." [1]
Environmental regulation. Roberts argued against the private citizen's right to sue the federal government for violations of environmental regulations in Lujan v. National Wildlife Federation.
[edit]
Private Law Practice
(arguing the positions formulated by his clients)
Environmental regulation. Roberts argued on behalf of the National Mining Association in support of the legality of mountaintop removal, in the case Bragg v. West Virginia Coal Association. 125 people had been killed and 50 million dollars in damages caused 30 years earlier in West Virginia when a mountaintop removal or MTR valley-fill burst.
Business-labor relations. In a case before the Supreme Court, Roberts argued on behalf of mining companies who wanted to use criminal contempt fines to force the end of a strike which had been ruled unlawful. The case, International Union, United Mine Workers Of America, et al. v. John L. Bagwell, et al., ended in a ruling in favor of the unions, with the majority opinion authored by Justice Blackmun. [2]
[edit]
Judicial Opinions
[edit]
During a Confirmation Hearing
Abortion. In 2003, during his confirmation hearing for appointment to the U.S. Court of Appeals for the District of Columbia Circuit, Roberts responded to a senator's question about Roe v. Wade: "Roe v. Wade is the settled law of the land...There is nothing in my personal views that would prevent me from fully and faithfully applying that precedent." Roberts was subsequently approved by a unanimous vote of the Senate.
It is likely that Roberts's own opinion on abortion and birth control will be questioned during his confirmation hearings before the U.S. Senate Committee on the Judiciary.
[edit]
Opinions as Judge on the U.S. Court of Appeals
Fourth and Fifth Amendments. The D.C. Circuit case Hedgepeth v. Washington Metro Authority involved a twelve-year-old girl who was taken into custody, handcuffed, and driven to police headquarters because she ate a french fry in a Washington metro station. Roberts wrote for a 3-0 panel affirming a district court decision that dismissed the girl's complaint, which was predicated on the Fourth and Fifth amendments. Roberts began his opinion by noting that "No one is very happy about the events that led to this litigation," and pointing out that the policies under which the girl was "apprehended" have since been changed. Roberts concluded the court was not authorized to second-guess the appropriateness of the District's policies: "The question before us," Roberts wrote, "is not whether these policies were a bad idea, but whether they violated the Fourth and Fifth Amendments to the Constitution."
Civil rights. In Hamdan v. Rumsfeld, Roberts joined the majority in upholding military tribunals set up by the Bush administration for trying terrorism suspects, overturning the district court ruling. [3]
Environmental regulation. On the U.S. Court of Appeals, Roberts wrote a dissenting opinion siding with a developer in a case involving the protection of a rare Californian toad under the Endangered Species Act. He argued that the interstate commerce clause of the Constitution did not permit the government to regulate activity affecting what he called "a hapless toad" that "for reasons of its own lives its entire life in California."
[edit]
Sources
Wikinews has a related story:
Bush Nominates John G. Roberts for U.S. Supreme CourtNews articles
"Appellate judge Roberts is Bush high-court pick." MSNBC. July 19, 2005. [4]
"Who Is John G. Roberts Jr.?" ABC News. July 19, 2005. [5]
"John G. Roberts, Jr. Fact Sheet" La Lumiere School. [6]
Barbash, Fred, et al: "Bush to Nominate Judge John G. Roberts Jr." Washington Post. July 19, 2005. [7]
Becker, Jo, and R. Jeffrey Smith. "Record of accomplishment—and some contradictions." Washington Post. July 20, 2005. [8]
Bumuller, Elisabeth, and David Stout: "President Chooses Conservative Judge as Nominee to Court." New York Times. July 19, 2005. [9]
Entous, Adam. "Bush picks conservative Roberts for Supreme Court." Reuters. July 19, 2005. [10]
Groppe, Maureen and Tuohy, John. "'If you ask John where he's from, he says Indiana'" The Indianapolis Star. July 20, 2005 [11]
Guren, Adam M. "Alum Tapped for High Court." Harvard Crimson. July 19, 2005. [12]
McFeatters, Ann. "John G. Roberts Jr. is Bush choice for Supreme Court." Pittsburgh Post-Gazette. July 19, 2005. [13]
Riechmann, Deb. "Federal judge Roberts is Bush's choice." Associated Press. July 20, 2005. [14]
Government/official
"President announces Judge John Roberts as Supreme Court nominee." Office of the Press Secretary, Executive Office of the President. [15]
"Roberts, John G., Jr." Federal Judicial Center. [16]
"John G. Roberts biography." Office of Legal Policy, U.S. Department of Justice. [17]
"Biographical Sketches of the Judges of the U.S. Court of Appeals for the DC Circuit." United States Court of Appeals for the District of Columbia Circuit. [18]
John G. Roberts Questionnaire for Appeals Court Confirmation Hearing (p. 297-339) and responses to Questions from Various Senators (p. 443-461) [19] (large PDF file)
Other
Coffin, Shannen W. "Meet John Roberts: The President Makes the Best Choice." National Review Online. July 19, 2005. [20]
Rosen, Jeffrey. "Evaluating Strict Constructionists: How to Judge." New Republic. November 29, 2004. [21]
John G. Roberts federal campaign contributions." Newsmeat.com. July 19, 2005. [22]
"John G. Roberts Jr." DKosopedia. July 19, 2005. [23]
"Report of the Alliance for Justice: Opposition to the Confirmation of John G. Roberts to the U.S. Court of Appeals for the D.C. Circuit." Alliance for Justice. URL accessed on July 19, 2005. [24] (PDF file)
"'If you ask John where he's from, he says Indiana'"[25]
A higher resolution picture from the article:
http://www.lmorovan.com/CDEX/cdex.htm
Click on picture.
Hospital Tests Intravenous Drug Technology
This post looks better...
http://www.nursezone.com/job/DevicesandTechnology.asp?articleID=14097Michigan
By Christina Orlovsky, senior staff writer
The prevention of medication errors has always been a concern of pharmacists, lab technicians, nurses and physicians. Several new technologies, including bar coding and robotic pharmacies, have helped reduce the risk of error occurring with oral medications, but not much has been done to improve the safety of intravenous drugs—until now. Pharmacists at the University of Michigan’s C.S. Mott Children’s Hospital, in Ann Arbor, Michigan, are piloting a new technology aimed at verifying the identity and concentration of high-risk IV medications.
The ValiMed System, created by ValiMed, Inc., flashes an ultraviolet (UV) light into one-milliliter samples of medication. Each medication has a unique “fingerprint,” called a fluorescence signature, which can be detected in 30 seconds by the UV light, explained Jim Stevenson, Pharm.D., the director of pharmacy services for the University of Michigan Health System. The pharmacists compare the signature with the prescribed concentration before sending the drug out to the patient.
Originally developed to detect explosives, the ValiMed System made its foray into health care in three hospitals that use the technology to test narcotic drug returns in the operating room. C.S. Mott Children’s Hospital is the first facility to use the ValiMed System for this intravenous drug purpose.
“We were looking for a way to make the medication system safer because we know that occasionally, even with experienced pharmacists and technicians, human error can make it past the checks and practices of the hospital pharmacy. Particularly with high-risk intravenous drugs, we wanted to eliminate that human error,” Stevenson said. “When I discovered that the ValiMed System was being used to detect narcotics, I thought, why couldn’t it be used to test high-risk drugs as well?”
Stevenson worked with ValiMed, Inc., to develop the capability and decided the system would work well in the pharmacy setting. In June, the hospital began creating signatures for the top 10 high-risk medications, as determined by the pharmacy staff and a host of published studies. Among these medications are insulin, blood thinners such as heparin, painkillers like morphine and the antibiotic vancomycin. According to Stevenson, all of the medications can produce toxic effects if administered incorrectly.
While the testing of the medications takes place in the pharmacy, the ValiMed System also has an enormous impact on the nursing staff.
“From a nurse’s perspective, when an error happens in the pharmacy with intravenous drugs, there is no way for a nurse to detect and prevent that error because they are dealing with clear liquids. Nurses have to trust that the drug that’s in the bag and its concentration are correct, and they have no way to head it off if it’s not,” Stevenson explained. “This system gives them some added peace of mind and another layer of security to make sure their patient is getting the right drug and concentration.”
For more information, visit the ValiMed Web site.
© 2005. AMN Healthcare, Inc. All Rights Reserved.
It's good to have you both back. We may differ on a few small points, but we are together in our opinions of CDEX the success!
Again fella's becareful what you post. Not only will the neighbors gang TOS you, but you may end up in the jail house. Even Coquille was put in the jail house. Go figure?
Right arm, INET!!!
Good to have you back with your straightforward opinions.
pCf
pigsCANfly, I urge you to be careful what you post. I am sure that you have been reported, and I don't want to see you end up in the IHub jail. I am not trying to tell you what to do. I understand your anger. Be good. V65
The other IHub CDEX board is were almost all the posters are "non-shareholders"! They are the very ones who were expelled from RB, and have been negative on CDEX for way to many years to count! Their interest in our investment has to make one question their motivation. One thing for sure, they are not here in our best interest. IMHO!
Ignoring them is the best response. Please don't turn this board into RB. I will pull any posts that have to. Pretend they are not there, and we can have a wonderful forum here on IHub.
Thanks, Viking65 (off to see a Buddy Holly show)
I wonder if a certain poster will get the idea that he's not wanted here and should go back to his own putrid board.
pCf
The IHub CDEX Inc (CEXI) board:
http://www.investorshub.com/boards/board.asp?board_id=1176
Vali-Med in ANN ARBOR, MI - Every year, pharmacists at the University of Michigan’s C.S. Mott Children’s Hospital prepare a million doses of medicines for thousands of young and often very ill patients.
(I-Newswire) - And because many of those medicines don’t come in sizes or strengths for use in babies, children and teenagers, the pharmacists and technicians must mix many doses themselves. For some drugs, the smallest error in preparation can be a matter of life and death — so the pharmacy team takes special care to double-check every one.
Now, their team has a new member who adds one more level of safety to the mixing and dispensing of high-risk intravenous drugs like blood thinners and painkillers. But it’s not a person. And it started its career not in a pharmacy, but in bomb detection.
In fact, the new team member is a two-foot-long blue machine called the ValiMed system, which sits on the countertop in the Mott pharmacy. It flashes ultraviolet light into tiny samples of medicines, instantly checking their identity and concentration just before they’re sent to a patient. The system is based on the fact that for most drugs a unique “fingerprint,” called a fluorescence signature, can be detected when they are exposed to ultraviolet ( UV ) light. Every drug’s fingerprint is different.
Courtesy of ValiMed, Inc.
The Mott pharmacy team has already added the ValiMed system to their process for preparing 10 commonly used and high-risk drugs; this chart shows how the "validation" step fits into the pharmacy work flow.
The U-M Health System is the first medical center in the world to use ValiMed for this purpose. The technology was first developed to detect explosives, and is being used at three other hospitals to verify that narcotic drugs aren’t being diverted.
U-M Pharmacy Services Director Jim Stevenson, Pharm.D., says the ValiMed system eliminates the small amount of potential for human error that remains even with a skilled, trained and experienced pharmacy team.
“No matter what we humans do to check, double-check, and triple-check our work, there’s still that chance for an error to slip through — and with children especially there’s a lot of drug preparation and the risk to the patient from a medication error can be catastrophic,” says Stevenson. “In this case, the technology can assure us that we’re giving the patient the right drug, in the right concentration, just before it goes to the patient’s room. It is the ultimate final check.”
The system is currently in use at Mott Hospital, and another ValiMed system may soon be installed at the main University Hospital that treats adults.
Stevenson and his pharmacy teams have devoted tremendous time and effort to patient safety in recent years, as part of the U-M Health System’s overall push to prevent errors and near-misses, to learn from experience and to ensure high-quality care.
The ValiMed system fits well into that effort, using technology to make absolutely sure that high-risk medications are prepared correctly.
Courtesy of ValiMed, Inc.
When exposed to ultraviolet ( UV ) light, every drug has its own characteristic "fingerprint"; three drugs' fingerprints are shown here. The ValiMed system checks drug samples against a library of stored fingerprints, acting as a foolproof check before medicines are given to patients.
In fact, the U-M pharmacy team has worked with ValiMed staff in recent months to set the standards that the machine uses to identify drugs. Every time it scans a one-milliliter sample of a medication, the machine compares the sample’s fluorescence “fingerprint” with a library of standard fingerprints in its memory. U-M pharmacists worked with the manufacturers of ValiMed to create that library for high risk medications, and performed pilot testing of the system before implementing it at Mott.
The current reference library includes ten commonly used intravenous drugs that need to be mixed specially for children and carry an especially high risk if they are delivered in the wrong concentration or to the wrong patient.
They include insulin, used to bring down blood sugar; heparin, used to thin blood; epinephrine, used to support blood pressure and cardiac function; narcotics such as morphine that reduce pain; and antibiotics such as vancomycin that can tame infections but can also be toxic if an incorrect dose is given.
Often, Stevenson says, pharmacists will make a batch of these drugs to dispense to many patients, using bulk medications and IV solution to dilute them so they can be delivered intravenously. Then, for each patient who needs the drug, the pharmacist will fill an IV bag or syringe for the nurse to administer. This means that if a mistake is made in creating the batch, many patients can suffer.
With ValiMed in place, the Mott pharmacists have incorporated a new step into their routine: they draw a tiny sample of the finished IV product, place it in a small square test tube that plugs into the top of the ValiMed machine, wait approximately 30 seconds, and read the machine’s display. It tells them if the fluorescence fingerprint from the sample matches the fingerprint for the same drug and concentration from the library.
The Mott team plans to develop more drugs in the ValiMed reference library, and to perfect the process for using the machine as part of their routine procedure. Other possible future uses include validating the identity and dose of chemotherapy drugs used in cancer patients.
“We know that medication errors are already extremely rare at Mott, and anywhere at U-M, but our goal is to not have any at all,” says Stevenson. “This system will give us, and our patients and their parents, a little more peace of mind that we’re doing all we can to prevent errors. This is part of our mission to be a leader in medication and patient safety.”
Stevenson credits Darrell Campbell, M.D., chief of staff for the U-M Hospitals & Health Centers, and others in the U-M Office of Clinical Affairs, for providing initial funding for the system. He also notes the role of Mott Pharmacy supervisor Denise Glenn, BS Pharm., Clinical Coordinator Deborah Pasko, Pharm.D., and pharmacist Hanna Phan, Pharm.D., for their role in implementing the system.
Written by Kara Gavin
OPPS! The link in my last post didn't work. So here are two really good Google links to Valimed and CDEX!
http://www.google.com/search?hl=en&lr=&q=+site:www.valimed.com+Valimed
http://www.google.com/search?hl=en&lr=&q=Cdex-Inc.&btnG=Search
I just received this google alert for Valimed via email.
Google Alert for: Valimed
StockSelector.com Message #84048 for CEXI
TWO OTHER LINKS FOR RESEARCH ON CDEX/VALIMED ...
http://www.google.com/search?
hl=en&lr=&q=+site:www.valimed.com+Valimed ...
I see the fox has been put in charge of the hen house. What a slap in the face to CDEX shareholders. The man who has tried to sink CDEX for years. No names were put in this post so it wont be pulled. Travesty and injustice.
First in World to Use New Light-based System to Check Prescription
By: U-M News on Jul 05 2005 08:57:38
http://www.emaxhealth.com/94/2491.html
advertisement
Prescription Drug Safety
Pharmacists can verify prescription drug identity and concentration to protect patient safety
Every year, pharmacists at the University of Michigan's C.S. Mott Children's Hospital prepare a million doses of medicines for thousands of young and often very ill patients.
And because many of those medicines don't come in sizes or strengths for use in babies, children and teenagers, the pharmacists and technicians must mix many doses themselves. For some drugs, the smallest error in preparation can be a matter of life and death, so the pharmacy team takes special care to double-check every one.
Now, their team has a new member who adds one more level of safety to the mixing and dispensing of high-risk intravenous drugs like blood thinners and painkillers. But it's not a person. And it started its career not in a pharmacy, but in bomb detection.
In fact, the new team member is a two-foot-long blue machine called the ValiMed system, which sits on the countertop in the Mott pharmacy. It flashes ultraviolet light into tiny samples of medicines, instantly checking their identity and concentration just before they're sent to a patient. The system is based on the fact that for most drugs a unique "fingerprint," called a fluorescence signature, can be detected when they are exposed to ultraviolet (UV) light. Every drug's fingerprint is different.
The U-M Health System is the first medical center in the world to use ValiMed for this purpose. The technology was first developed to detect explosives, and is being used at three other hospitals to verify that narcotic drugs aren't being diverted.
U-M Pharmacy Services Director Jim Stevenson, Pharm.D., says the ValiMed system eliminates the small amount of potential for human error that remains even with a skilled, trained and experienced pharmacy team.
"No matter what we humans do to check, double-check, and triple-check our work, there's still that chance for an error to slip through and with children especially there's a lot of drug preparation and the risk to the patient from a medication error can be catastrophic," says Stevenson. "In this case, the technology can assure us that we're giving the patient the right drug, in the right concentration, just before it goes to the patient's room. It is the ultimate final check."
The system is currently in use at Mott Hospital, and another ValiMed system may soon be installed at the main University Hospital that treats adults.
Stevenson and his pharmacy teams have devoted tremendous time and effort to patient safety in recent years, as part of the U-M Health System's overall push to prevent errors and near-misses, to learn from experience and to ensure high-quality care.
The ValiMed system fits well into that effort, using technology to make absolutely sure that high-risk medications are prepared correctly.
In fact, the U-M pharmacy team has worked with ValiMed staff in recent months to set the standards that the machine uses to identify drugs. Every time it scans a one-milliliter sample of a medication, the machine compares the sample's fluorescence "fingerprint" with a library of standard fingerprints in its memory. U-M pharmacists worked with the manufacturers of ValiMed to create that library for high risk medications, and performed pilot testing of the system before implementing it at Mott.
The current reference library includes ten commonly used intravenous drugs that need to be mixed specially for children and carry an especially high risk if they are delivered in the wrong concentration or to the wrong patient.
They include insulin, used to bring down blood sugar; heparin, used to thin blood; epinephrine, used to support blood pressure and cardiac function; narcotics such as morphine that reduce pain; and antibiotics such as vancomycin that can tame infections but can also be toxic if an incorrect dose is given.
Often, Stevenson says, pharmacists will make a batch of these drugs to dispense to many patients, using bulk medications and IV solution to dilute them so they can be delivered intravenously. Then, for each patient who needs the drug, the pharmacist will fill an IV bag or syringe for the nurse to administer. This means that if a mistake is made in creating the batch, many patients can suffer.
With ValiMed in place, the Mott pharmacists have incorporated a new step into their routine: they draw a tiny sample of the finished IV product, place it in a small square test tube that plugs into the top of the ValiMed machine, wait approximately 30 seconds, and read the machine's display. It tells them if the fluorescence fingerprint from the sample matches the fingerprint for the same drug and concentration from the library.
The Mott team plans to develop more drugs in the ValiMed reference library, and to perfect the process for using the machine as part of their routine procedure. Other possible future uses include validating the identity and dose of chemotherapy drugs used in cancer patients.
"We know that medication errors are already extremely rare at Mott, and anywhere at U-M, but our goal is to not have any at all," says Stevenson. "This system will give us, and our patients and their parents, a little more peace of mind that we're doing all we can to prevent errors. This is part of our mission to be a leader in medication and patient safety."
Stevenson credits Darrell Campbell, M.D., chief of staff for the U-M Hospitals and Health Centers, and others in the U-M Office of Clinical Affairs, for providing initial funding for the system. He also notes the role of Mott Pharmacy supervisor Denise Glenn, BS Pharm., Clinical Coordinator Deborah Pasko, Pharm.D., and pharmacist Hanna Phan, Pharm.D., for their role in implementing the system.
From : Malcolm H. Philips, Jr. <mphilips@cdex-inc.com>
Sent : Saturday, June 11, 2005 6:36 PM
To :xxx xxxxx
Subject : RE: update
/ / / Inbox
Mr.:xxxxx Thanks for your interest in CDEX. See messages we have
previously communicated to shareholders, below re your two areas of
questions.
"For shareholders that are use to communications with more mature companies
or with companies such as the old Loch Harris that did their business in a
certain way, we can understand frustration. However, we are a new public
company. We have at least one additional [near term] filing with the SEC. We
are erring on the side of being very cautious and conservative regarding
potential selective disclosure. There is no useful purpose to be served in
disclosing in-process actions or completed actions that are not
strategically significant. The disclosures so far regarding clients have
resulted in those clients being "harassed" by not well meaning folks. So, we
will communicate with appropriate disclosures at the right time in the best
interest of the company. Logical folks who have the best interest of the
company at heart agree with this policy."
"To provide perspective for your question, as we understand, the legal
requirements for annual meetings are for them to occur sometime during the
company's FY, which ends Oct 31, as you may know. (My guess is that there
are exceptions for limited duration extensions, though we have not looked at
that at this time). We have not yet decided on the location or date. As
with our last annual meeting, we will comply with the legal requirements
regarding notice."
CDEX Management
-----Original Message-----
From:xxxx xxxxxx
Sent: Saturday, June 11, 2005 3:21 PM
To: mphilips@cdex-inc.com
Subject: update
Dear Sir:
Hello and to you and all the team at CDEX hope all of you enjoyed the past
Memorial Day as I did myself.
A few days ago 5/31 I sent you a message about an update for all share
holders. I still have not recieved an answer and can't understand what harm
it could do to communicate with share holders about the happenings at CDEX.
The same questions I asked before I will ask again. Is there anything news
worthy to announce about the recent trade shows? Is there going to be a
shareholders meeting if so when and where? Is there any reason that you can
not commmunicate with us? Would you please make a statement or announcement
that would address these questions. Any word from you positive or negitive
would be appreciated by all.
Best Regards
xxx
/ / / / /
CEXI - CDEX INC CL A
Page of 1
April 2005 March 2005 Year-to-Date
Volume Rank % Volume Rank % Volume Rank %
Total Share Volume 401,572
NITE
KNIGHT EQUITY MARKETS, L.P. 144,569 1 36 - - - 144,569 1 36
SCHB
UBS CAPITAL MARKETS L.P. 123,833 2 30 - - - 123,833 2 30
HDSN
HUDSON SECURITIES,INC. 80,655 3 20 - - - 80,655 3 20
TDCM
TD WATERHOUSE CAPITAL MARKETS, INC. 46,953 4 11 - - - 46,953 4 11
HILL
HILL THOMPSON MAGID & CO., INC. 3,363 5 <1 - - - 3,363 5 <1
TASL
Tradition Asiel Securities Inc. (TASL) 2,000 6 <1 - - - 2,000 6 <1
PERT
PERSHING TRADING COMPANY, L.P. 199 7 <1 - - - 199 7 <1
Page of 1
Copyright © 2004. The Nasdaq Stock Market, Inc. Please read our Disclaimer and Privacy Statem
Market Maker List
CEXI CDEX INC CL A
Download All Page of 1
May 26, 2005
MPID Market Maker Name MP Quote Status Trade Halt
Total MPID Count: 9
ETRD E*TRADE CAPITAL MARKETS LLC Active
GNET ARCHIPELAGO TRADING SERVICES, INC. Active
HDSN HUDSON SECURITIES,INC. Active
HILL HILL THOMPSON MAGID & CO., INC. Active
PERT PERSHING TRADING COMPANY, L.P. Active
SACM STERNE AGEE CAPITAL MARKETS, INC. Active
SCHB UBS CAPITAL MARKETS L.P. Active
TDCM TD WATERHOUSE CAPITAL MARKETS, INC. Active
VERT THE VERTICAL GROUP, INC. Active
Thank You Sassy Frasse! The CDEX(CEXI) shareholders appreciate you.
ValiMed Web Site updated..
http://www.valimed.com/
On the CDEX WEB SITE...
IN THE NEWS
CDEX Begins Trading on OTCBB
NEW YORK, April 14, 2005 /PRNewswire-FirstCall/ CDEX Inc. (OTC Bulletin Board – CEXI.OB), a developer of chemical detection technologies, announced today that it has begun trading on the OTC Bulletin Board, effective immediately.
“Listing on the OTC Bulletin Board should give the Company wider exposure to the investment community and further the process of introducing the company to the market areas that we are targeting,” said Malcolm Philips, President and CEO. “We have made a great deal of progress in the health care markets (contracts for multiple products in major hospitals) and the homeland security markets (expanding the development focus to include illegal drugs). We are developing cutting edge solutions to major problems facing this country and are excited about the relationships that we are building for the future.”
About CDEX :
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to the development of products in two distinct areas: (i) identification of substances of concern (e.g., explosives, illegal drugs and chemical/biological weapons); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication; detection of counterfeit or sub-par products for brand protection; and quality assurance inspection of incoming raw materials and outgoing final products). All CDEX products are based on applying the same underlying technologies for which we have patents pending. CDEX expects to acquire other technologies in the future through partnering and investment. However, at present, the company anticipates that almost all of its revenues, if any, will come from its chemical detection and validation products.
CDEX is headquartered in Rockville, Maryland and has its primary research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
http://www.cdex-inc.com/
CDEX PRESS RELEASE..April 14...
http://biz.yahoo.com/bw/050414/145836.html?.v=1
CDEX Begins Trading on OTCBB
Thursday April 14, 4:29 pm ET
NEW YORK--(BUSINESS WIRE)--April 14, 2005--CDEX Inc. (OTCBB:CEXI.OB - News), a developer of chemical detection technologies, announced today that it has begun trading on the OTC Bulletin Board, effective immediately.
"Listing on the OTC Bulletin Board should give the Company wider exposure to the investment community and further the process of introducing the company to the market areas that we are targeting," said Malcolm Philips, President and CEO. "We have made a great deal of progress in the health care markets (contracts for multiple products in major hospitals) and the homeland security markets (expanding the development focus to include illegal drugs). We are developing cutting edge solutions to major problems facing this country and are excited about the relationships that we are building for the future."
About CDEX :
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to the development of products in two distinct areas: (i) identification of substances of concern (e.g., explosives, illegal drugs and chemical/biological weapons); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication; detection of counterfeit or sub-par products for brand protection; and quality assurance inspection of incoming raw materials and outgoing final products). All CDEX products are based on applying the same underlying technologies for which we have patents pending. CDEX expects to acquire other technologies in the future through partnering and investment. However, at present, the company anticipates that almost all of its revenues, if any, will come from its chemical detection and validation products.
CDEX is headquartered in Rockville, Maryland and has its primary research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
lmorovan another confrontational post by you, yet again! I can read English! Stop insulting people! Also CEXI is the symbol for CDEX! So obviously when you post about CEXI, you post about CDEX! How obvious is that? Why is it that you cause problems wherever you post? You are not being true to your word. FACT! Proven and convicted by you own words! Give it a break, and go back to raging Bull please stop ruining this board!
Viking65, in case you didn't notice, that excerpt of a post was on the RB board. This happens to be IHub board. Either way, I will keep my promise to not post about the company. But never promised not to post about CEXI, the management or shareholders. I hope your English is good enough to read my words, and not what is not written.
By lmorovan; "I hope and pray that things will be better in the next year.
I promise, the day CDEX starts actually selling products, reporting revenues and become public and trading, I will stop posting about the company".
Let's see if he lives up to his promise?
Thanks Tex. Looking forward to it. I still don't understand why this board has (old) next to the title? Makes no sense, when the other board is filed with....and a few very loyal real shareholders!
Thanks for the info. Doug eom
OTCBB Tomorrow......
http://www.otcbb.com/asp/dailylist_detail.asp?d=04/13/2005&mkt_ctg=OTCBB
Here is the link to the nursing magazine from which the article came from.
http://nsweb.nursingspectrum.com/NurseNewsEzine/item.cfm?ID=1787
It can also be found on the Cdex website. Link below.
http://www.cdex-inc.com
Utah Addresses Drug Diversion from OR
with New Analyzer
NurseNews e-zine
March 22, 2005
The University of Utah Hospital is one of the first in the country to tackle the problem of drug diversion at its source, with a new device that validates the contents of all returned narcotics from ORs.
Various studies have shown that 5% to 10% of anesthesiologists, nurses, and pharmacists have abused medications illegally by substituting saline or water for narcotics.
The shoebox-size device, called ValiMed, coupled with a proprietary library of chemical “fingerprints” and software, can help facilities document compliance with JCAHO standards for controlled substances, says maker CDEX, in Rockville, Md.
In seconds, the device provides a spectral analysis of the contents of returned syringes to ensure they contain narcotics, which “pretty much eliminates a major source of narcotic drug diversion,” says Jim Jorgenson, associate dean for clinical affairs, University of Utah College of Pharmacy.
He says the University of Utah’s Huntsman Cancer center also is launching a trial of the analyzer in its oncology department to ensure the accuracy of compounded chemotherapy injections.
Source:
http://nsweb.nursingspectrum.com/NurseNewsEzine/item.cfm?ID=1787
Pure unadultrated bashing, as we have learned to expect from you.
CDEX-INC. A nice compilation of info regarding our company and what professionals think of it. Found this on another board: Thanks, Viking65
April 2005 USP797 Sterile Compounding New NIOSH Guidelines plus PhaSeal
http://www.pharmacy.utah.edu/continuinged/USP%20brochure.pdf
New NIOSH Guidelines
Jim Jorgenson, RPh., MS, FASHP,
Director of Pharmacy Services,
University of Utah, College of Pharmacy,
Salt Lake City, UT
The University of Utah College of
Pharmacy is accredited by the
Accreditation Council for Pharmacy
Education as providers of continuing
pharmacy education.
= = = = = = =
State why PhaSeal® is considered a closed
system when preparing cytotoxic drugs.
PhaSeal
Jim Jorgenson, RPh., MS, FASHP,
Director of Pharmacy Services,
University of Utah, College of Pharmacy,
Salt Lake City, UT
= = = = = = =
VERY IMPORTANT READING-Huntsman, Jorgenson, MD Anderson, PhaSeal etc
http://ww1.prweb.com/prfiles/2003/11/25/91277/HuntsmanStudy.pdf
= = = = = = =
A tidbit more regarding PhaSeal
http://www.prweb.com/releases/2003/7/prweb74462.php
MD Anderson and PhaSeal®: A Leader in Science Leads Adoption of New Closed System Technology For Safe Handling of Hazardous Drugs
http://www.prweb.com/releases/2004/5/prweb128807.php
http://www.in-pharmatechnologist.com/news/news-ng.asp?id=26607-phaseal-protects-cancer
PhaSeal protects cancer drug handlers
http://www.pshp.org/about_pshp.html
Established in 1970, the Pennsylvania Society of Health System Pharmacists (PSHP) is the fifth largest state affiliate of the American Society of Health-System Pharmacists.
http://www.pshp.org/midyear_programs.html
Pharmacists and Technicians Working Together for our Oncology Patients
Demonstrate and give an overview of the PhaSeal* closed system for chemotherapy preparation.
Discuss our experience training and educating technical staff for competency in IV chemotherapy preparation.
= = = = = = =
A tidbit more regarding USP797…
http://www.valimed.com/usp797_compliance/usp797compliance.htm
“New Technology Addresses USP 797 Worries”
The Solution
The ValiMed Regulatory Compliance Solution provides validation of your sterile preparations and documentation of your quality process to meet the USP 797 requirements.
The ValiMed solution gives the assurance that sterile admixtures have been manufactured accurately. This reduces undetected errors in medication selection, the manufacturing of admixtures, inadvertent substitution, or the mislabeling of the medication. If to err is human, then to prevent is ValiMed’s.
ValiMed combines a revolutionary new technology to validate medications, equally innovative software to define and automate the quality process, and a library of the unique spectral fingerprints for a range of relevant medications. As your needs expand, so too can this library.
With a flash of the VailMed light source, your personnel can compare the fingerprint of a given medication under review to a selected fingerprint from a library of spectral fingerprints. The ValiMed system registers a match—or a failure to match—between the fingerprint of a test sample and that of a chosen medication from the library. No interpretation of results is required. It’s that simple.
This allows for near real time medication validation and documentation of your quality process. Daily activity reports can be easily generated to comply with USP guidelines and to facilitate JCAHO surveys.
= = = = = = =
A tidbit more about Jim Jorgenson, RPh., MS, FASHP,Dir Phar Services Univ of Utah College of Pharmacy, and CDEX/Valimed …
http://www.valimed.com/media_center/pr/012605.htm
Press Release
University of Utah Health Sciences Center Addresses Narcotics Diversion
ValiMed system meets JCAHO and ASHP Standards by validating return of controlled substances from the operating room.
ROCKVILLE, Md. and SALT LAKE CITY, Ut.—January 26, 2005—Narcotic drug diversion is a long-standing problem for healthcare organizations. Many studies find that between five and 10 percent of anesthesiologists, nurses, and pharmacists have used this class of medications illegally. By substituting saline or water, narcotics-abusing clinicians had an undetectable source of drugs that compromised patient safety.
At the University of Utah Health Sciences Center, the University of Utah Hospital is one of the first hospitals in the country to tackle the problem at the source. Using ValiMed, a new device from CDEX, the hospital now validates the contents of all returned narcotics from the operating room.
“ValiMed pretty much eliminates a major source of narcotic drug diversion,” said Jim Jorgenson, Director of Pharmacy Services, and Associate Dean for Clinical Affairs, University of Utah College of Pharmacy. “Its spectral analysis ensures every returned syringe contains narcotics and not just water. The machine is the size of a shoebox and fits in our satellite pharmacy; any pharmacy technician can perform the validation in seconds.”
“University of Utah is a perfect partner for us,” noted Malcolm Philips, CEO of CDEX. “Besides the obvious value of proving capabilities, the staff’s input was invaluable. They helped us take a good product to great, ensuring we delivered a device that worked just as well in the real world as it does in the lab. This reflects the second client to successfully complete the two month acceptance test which is included in our sales contracts.”
The system comprises three components: the instrument, a proprietary library of chemical “fingerprints,” and process automation software. The reporting capabilities of the system can help healthcare organizations document compliance with JCAHO standards for controlled substances.
“The success of the implementation proved the value of the device,” said Jorgenson. “It also got us thinking about other ways it could help us. We are launching another CDEX pilot in the pharmacy at the University of Utah’s Huntsman Cancer Institute to provide additional assurance that our compounded chemotherapy injections are correct. Putting medication validation at the front end will help us eliminate medication error.”
“Looking forward, we expect to expand the use of ValiMed to all of our OR and oncology pharmacies,” added Jorgenson. ‘We are also interested in working with CDEX as they develop additional uses for their ValiMed products.”
Jorgenson noted that using ValiMed for pre-administration drug validation may require additional testing to comply with applicable FDA and other legal requirements.
About University of Utah Health Science Center
The University of Utah Health Sciences Center includes a medical school; colleges of Pharmacy, Nursing, and Health and comprehensive clinical services that include the University of Utah Hospital, University of Utah Neuropsychiatric Institute, Huntsman Cancer Hospital and Huntsman Cancer Institute; Moran Eye Center, University of Utah Orthopaedic Center, a network of community clinics, and various other institutes and centers. The health sciences center excels in education, research, patient care and community outreach throughout Utah and the Intermountain West.
For more information, please visit www.uuhsc.utah.edu
About CDEX
ValiMed is a line of CDEX products for the healthcare market. CDEX is a technology development company with headquarters in Rockville, Maryland and laboratories in Tucson, Arizona. CDEX is also developing products in other markets, including homeland security and brand protection.
For more information on ValiMed, please see www.ValiMed.com.
CEXI 1.5 0.05
More Info: News, Chart, Profile,
Quote ,Insider ,Options
Changes in the new filing:
For the first time, CDEX acknowledges the symbol CEXI.PK in its filing.
The $67,800 claimed in the last filing is missing.
Important from the latest filing.
o Counterfeit Medication Solution: Development is complete, production units
have been available for distribution since September 2004.
o Impaired Clinician: Development is complete, and production units have been
available for distribution since September 2004.
o Patient Safety Solution and Regulatory Compliance Solution: Development is
ongoing. We have produced a standalone prototype, but have yet to complete a
production prototype for a unit integrated directly into the pump that combines
the medications into a solution and then releases them into the intravenous
drip.
o PS(3): Development of a first generation prototype is complete. Final release
of the product is pending refinement (in coordination with the appropriate
government agency), manufacturer-ready engineering, and software modification.
o MS(3): Development is ongoing; assuming adequate funding, we anticipate a
production prototype within twelve months We have not completed software
development or a first generation prototype.
o AS(3): Development is ongoing; assuming adequate funding, we have not
completed software development or a first generation prototype; we anticipate a
prototype within twelve months.
o FS(3): Development is ongoing; assuming adequate funding, we have not
completed software development a first generation prototype; we anticipate a
prototype within twelve months.
o Distilled Spirits Counterfeit Detection Unit: Development is complete for a
first generation prototype. Further development awaits funding.
- - - - -
New CDEX SEC FILING 3-25
http://freerealtime.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=3562687&Type=ORIG
Another really good article about a CDEX product.
Utah Addresses Drug Diversion from OR with New Analyzer
The University of Utah Hospital is one of the first in the country to tackle the problem of drug diversion at its source, with a new device that validates the contents of all returned narcotics from ORs.
Various studies have shown that 5% to 10% of anesthesiologists, nurses, and pharmacists have abused medications illegally by substituting saline or water for narcotics.
The shoebox-size device, called ValiMed, coupled with a proprietary library of chemical “fingerprints” and software, can help facilities document compliance with JCAHO standards for controlled substances, says maker CDEX, in Rockville, Md.
In seconds, the device provides a spectral analysis of the contents of returned syringes to ensure they contain narcotics, which “pretty much eliminates a major source of narcotic drug diversion,” says Jim Jorgenson, associate dean for clinical affairs, University of Utah College of Pharmacy.
He says the University of Utah’s Huntsman Cancer center also is launching a trial of the analyzer in its oncology department to ensure the accuracy of compounded chemotherapy injections.
Great article!!! CDEX shareholders only. Let me guess who will find fault with this article. LOL
http://www.pppmag.com/documents/pp22spotlight.pdf
From the article:
"The ValiMed drug detection device is a self-contained, 9 by 10 by 21-inch unit that resides on a countertop, and requires only standard electrical power to function. The device uses a touch screen and Windows XP to provide a simple software user interface that facilitates the testing process."
"The ValiMed device provides us with the ability to test all of our returns and offers reliable, on-the-spot data, resulting in significant control and safety benefits."
"The pharmacy plans to expand its use of the ValiMed device to other surgical areas within the university health system."
"In addition, we are looking at ways to utilize the device's capabilities to validate chemotherapy preparations compounded in the university's Huntsman Cancer Hospital pharmacy and to perform QA concentration testing of bulk items manufactured in the central pharmacy."
"This, in turn, would improve compliance with JCAHO and state board of pharmacy recommendations for having good procedures in place to validate narcotic returns and prevent diversion. The solution needed to be practical, efficient and cost-effective enough to allow for daily use in the OR pharmacy satellite, and needed to provide a greater degree of specificity than could be attained using refractometry."
"Each medication reveals its own distinct and easiy readible signature. By comparing the fingerprints of a tested medication against the signature of that medication in the library, the ValiMed technology will indicate a match, presuming there is one."
"The device can validate the identity of most medications against samples in the library in less than 30 seconds."
10QSB..New filing: http://www.secinfo.com/d1526c.zCy.htm
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
516
|
Created
|
05/17/04
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |